Frontage Holdings Corp
HKEX:1521

Watchlist Manager
Frontage Holdings Corp Logo
Frontage Holdings Corp
HKEX:1521
Watchlist
Price: 1.67 HKD 0.6% Market Closed
Market Cap: 3.4B HKD
Have any thoughts about
Frontage Holdings Corp?
Write Note

Frontage Holdings Corp
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Frontage Holdings Corp
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Frontage Holdings Corp
HKEX:1521
Long-Term Debt
$113.3m
CAGR 3-Years
47%
CAGR 5-Years
109%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Long-Term Debt
$31.2B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
11%
Danaher Corp
NYSE:DHR
Long-Term Debt
$16.3B
CAGR 3-Years
-12%
CAGR 5-Years
0%
CAGR 10-Years
19%
Mettler-Toledo International Inc
NYSE:MTD
Long-Term Debt
$1.9B
CAGR 3-Years
5%
CAGR 5-Years
11%
CAGR 10-Years
18%
Agilent Technologies Inc
NYSE:A
Long-Term Debt
$3.3B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
7%
IQVIA Holdings Inc
NYSE:IQV
Long-Term Debt
$12.3B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
20%
No Stocks Found

Frontage Holdings Corp
Glance View

Market Cap
3.4B HKD
Industry
Life Sciences Tools & Services

Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania. The company went IPO on 2019-05-30. Its segments include North America and the People’s Republic of China (PRC). Its North America segment, including laboratory testing, chemistry, manufacturing and control (CMC), preclinical research and chemistry services in the United States of America and Canada. Its PRC segment including laboratory testing, CMC, preclinical research, bioequivalence clinical and chemistry services in the PRC. Its preclinical research includes drug metabolism and pharmacokinetic (DMPK), safety, chemical and toxicology, and laboratory testing, including bioanalytical and biologics, and central laboratory. Its services and solutions include drug candidate evaluation, product development, clinical services and central laboratory and testing services.

Intrinsic Value
2.65 HKD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Frontage Holdings Corp's Long-Term Debt?
Long-Term Debt
113.3m USD

Based on the financial report for Dec 31, 2023, Frontage Holdings Corp's Long-Term Debt amounts to 113.3m USD.

What is Frontage Holdings Corp's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
109%

Over the last year, the Long-Term Debt growth was 21%. The average annual Long-Term Debt growth rates for Frontage Holdings Corp have been 47% over the past three years , 109% over the past five years .

Back to Top